Ahmed Sawas Selected Research

Stem Cell Transplantation

1/2018	Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
11/2016	High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ahmed Sawas Research Topics

Disease

10	Neoplasms (Cancer) 01/2021 - 08/2015
8	Hodgkin Disease (Hodgkin's Disease) 01/2021 - 11/2016
7	Lymphoma (Lymphomas) 03/2024 - 01/2018
4	T-Cell Lymphoma (Lymphoma, T Cell) 03/2024 - 01/2018
4	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 02/2020 - 08/2015
3	Hematologic Neoplasms (Hematological Malignancy) 01/2021 - 08/2015
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2021 - 01/2017
2	Exanthema (Rash) 01/2020 - 01/2018
2	Thrombocytopenia (Thrombopenia) 01/2020 - 01/2019
2	Neutropenia 01/2020 - 01/2018
2	Sepsis (Septicemia) 01/2018 - 03/2008
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2024
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2021
1	Ataxia Telangiectasia (Louis Bar Syndrome) 09/2020
1	Multiple Myeloma 01/2020
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2020
1	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2020
1	Waldenstrom Macroglobulinemia (Macroglobulinemia) 01/2020
1	Fatigue 01/2020
1	Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated) 01/2019
1	Stomatitis 01/2018
1	Residual Neoplasm 01/2016
1	Drug-Related Side Effects and Adverse Reactions 08/2015
1	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 08/2015
1	Septic Shock (Toxic Shock Syndrome) 03/2008

Drug/Important Bio-Agent (IBA)

6	Brentuximab VedotinIBA 12/2020 - 11/2016
5	Bendamustine Hydrochloride FDA Link 12/2020 - 01/2018
4	romidepsin (FK228)FDA Link 03/2024 - 01/2018
4	Histone Deacetylase InhibitorsIBA 03/2024 - 08/2015
3	10-propargyl-10-deazaaminopterin FDA Link 03/2024 - 11/2017
2	Rituximab (Mabthera)FDA Link 01/2021 - 01/2017
2	belinostatIBA 01/2020 - 08/2015
2	Monoclonal AntibodiesIBA 01/2019 - 01/2017
1	Folic Acid AntagonistsIBA 03/2024
1	Drug CombinationsIBA 01/2021
1	TTI-621IBA 01/2021
1	ricolinostatIBA 01/2021
1	NivolumabIBA 01/2021
1	2- (2,6- dimethylmorpholin- 4- yl)- N- (5- (6- morpholin- 4- yl- 4- oxo- 4H- pyran- 2- yl)- 9H- thioxanthen- 2- yl)acetamideIBA 09/2020
1	Lenalidomide (CC 5013)FDA Link 01/2020
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2020
1	Alanine Transaminase (SGPT)IBA 01/2020
1	CreatinineIBA 01/2020
1	Chimeric Antigen ReceptorsIBA 01/2020
1	Azacitidine (5 Azacytidine)FDA Link 10/2019
1	mogamulizumabIBA 01/2019
1	CC ChemokinesIBA 01/2019
1	Proteins (Proteins, Gene)FDA Link 01/2019
1	Immunoconjugates (Immunoconjugate)IBA 12/2018
1	ublituximabIBA 01/2017
1	Immune Checkpoint InhibitorsIBA 11/2016
1	Histone Deacetylases (Histone Deacetylase)IBA 08/2015
1	Brain Natriuretic Peptide (Natrecor)FDA Link 03/2008
1	CytokinesIBA 03/2008
1	Biomarkers (Surrogate Marker)IBA 03/2008

Therapy/Procedure

7	Drug Therapy (Chemotherapy) 01/2024 - 01/2018
3	Therapeutics 02/2020 - 01/2016
2	Stem Cell Transplantation 01/2018 - 11/2016
1	Aftercare (After-Treatment) 02/2020
1	Salvage Therapy 01/2020